Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing using *in silico* Structure-based Virtual Screening Approach

Shweta Choudhary[1], Yashpal S. Malik[2], Shailly Tomar[1*]
[1]Department of Biotechnology, Indian Institute of Technology Roorkee, Uttarakhand (247667), India.
[2]Division of Biological Standardization, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh 243122, India.

*Corresponding author details

    Dr. Shailly Tomar
    Professor,
    Department of Biotechnology,
    Indian Institute of Technology Roorkee,
    Uttarakhand, India 247 667
    Tel: +91-1332-285849
    Fax: 91-1332-273560
    Email: shailly.tomar@bt.iitr.ac.in, shaiprav@gmail.com

ABSTRACT

The rapidly spreading, highly contagious and pathogenic SARS-coronavirus 2 (SARS-CoV-2) associated Coronavirus Disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization (WHO). The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycoprotein (S-protein) to cellular angiotensin converting enzyme 2 (ACE2) receptor. The virus specific molecular interaction with the host cell represents a promising therapeutic target for identifying SARS-CoV-2 antiviral drugs. The repurposing of drugs can provide a rapid and potential cure towards exponentially expanding COVID-19. Thereto, high throughput virtual screening approach was used to investigate FDA approved LOPAC library drugs against both the S-RBD and ACE2 host cell receptor. Primary screening identified a few promising drugs for both the targets, which were further analysed in details by their binding energy, binding modes through molecular docking, dynamics and simulations. Evidently, GR 127935 hydrochloride hydrate, GNF-5, RS504393, TNP and eptifibatide acetate were found binding to virus binding motifs of ACE2 receptor. Additionally, KT203, BMS195614, KT185, RS504393 and GSK1838705A were identified to bind at the receptor binding site on the viral S-protein. These identified drug molecules may effectively assist in controlling the rapid spread of SARS-CoV-2 by not only potentially inhibiting the virus at entry step but also as anti-inflammatory agents which could impart relief in lung inflammation. Timely identification and determination of an effective drug to combat and tranquilize the COVID-19 global crisis is the utmost need of hour. Further, prompt *in vivo* testing to validate the anti-SARS-CoV-2 inhibition efficiency by these drugs could save lives is justified.

INTRODUCTION

The world is facing a dire situation of global public health emergency due to a viral pandemic of severe febrile pneumonia like respiratory syndrome caused by a novel coronavirus, named SARS-CoV-2, causing the COVID-19 disease. SARS-CoV-2, a member of the *Coronaviridae* family, is a type of positive-sense, single-stranded enveloped RNA viruses responsible for causing infections in avian, mammalian and marine species across the world (1). Clinical onset of infection in COVID-19 is characterized by symptoms as headache, dry cough, and fever; in severe cases multi-organ failure, and even deaths (2). As of April 13th 2020, the outbreak has adversely affected more than 18, 00,000 people globally, and about 100,000 deaths have already been reported from Mainland China and rest of the 213 affected countries (3).

Infections caused by alpha-coronaviruses (NL63-CoV and HCoV-229E) are usually mild and asymptomatic, whereas beta-coronaviruses like severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), have caused serious epidemics (4). In the year 2002, SARS-CoV emerged as an epidemic in China and resulted in approximately 8000 reported cases (5). Recurrence in the form of MERS-CoV was later reported in Saudi Arabia, with a fatality rate of 35% (6,7). NL63-CoV, HCoV-OC43, and HCoV-HKU1 are a few other coronaviruses responsible for causing infections in humans (8).

Re-emergence of coronaviruses, as SARS-CoV-2 in the end of year 2019, has put the world on high alert and has created an alarming situation demanding an urgent treatment to preclude the potential death of infected patients (9,10). Despite extensive efforts worldwide by researchers, there are still no effective antiviral drugs or therapies available that could treat patients or prevent the virus transmission. Current prevention and treatment efforts are directed on quarantine and containment of infected patients to prevent human to human transmission (10,11). However, reports are available on repurposing the antiviral drugs like remdesivir, lopinavir, ritonavir, and anti-malarial drug chloroquine against SARS-CoV-2 (12). Additionally, neutralizing monoclonal antibody-based therapeutics are also being developed to combat COVID-19 crisis (13,14).

Coronavirus infection in humans is driven mainly by interactions between envelope-anchored spike glycoprotein (S-protein) of CoV and the host cell receptor, angiotensin-converting enzyme 2 (ACE2) (15,16). The S-protein is made up of two subunits, S1 as the receptor-binding domain (RBD) and S2 subunit is responsible for the fusion of viral membrane and the host cellular membrane (17). S2 subunit of SARS-CoV-2 is highly conserved with ~99% similarity whereas the S1 subunit shares 70% similarity with other bat SARS-CoV and human SARS-CoV, but the core RBD domain is highly conserved among them (9,18). Furthermore, the residues of S-RBD of SARS-CoV-2 are highly conserved when compared to SARS-CoVs from bats, human, and palm civet cat. The affinity between S-RBD of SARS-CoV-2 and ACE2 is found to be approximately ten times higher when compared with SARS-CoV RBD (year 2003), implying that ACE2 is the specific receptor which is responsible for the

binding of virus to the host cell membrane (7,19). Evidently, the key residues of SARS-CoV RBD (Tyr442, Leu472, Asn479, Asp480 and Thr487) are hypothesized to have undergone natural selection in SARS-CoV-2 and have been proposed to play a critical role in cross-species transmission of coronaviruses (19). Based on previous studies, Lys31 and Lys353 located on ACE2 are considered to be virus-binding hotspot residues liable for binding of S-protein (1,20). In human ACE2 receptor, hotspot 31(Lys31) is made up of salt bridge between Lys31 and Glu35, and hotspot 353 is made up of another salt bridge between Lys353 and Asp38, surrounded by a hydrophobic environment (20). SARS-CoV-2 recognizes human ACE2 by its residue Gln493 and Leu455, which are proposed to form favorable molecular interactions with hotspot 31, thereby enhancing viral binding to human ACE2. Additionally other key residues of S-protein provide more support for hotspot 31(SARS-CoV-2: Leu455, Phe486, Ser494; SARS-CoV: Tyr442, Leu472 and Asp480). In SARS-CoV-2, residue 494 which is a serine also strengthens structural stability of hotspot 353 (Lys 353) of ACE2 receptor (1).

Intriguingly, detailed molecular analysis and characterization of these interactions between ACE2 receptor and S-RBD of SARS-CoV-2 is essential to develop vaccines or therapeutic drugs for prevention and treatment of infections SARS-CoV-2. Computational screening of large libraries of drugs can be done against SARS-CoV-2 targets, based on epitopes, polyprotein, S-RBD domain of SARS-CoV-2, or for the virus receptor ACE2. Repurposing them for coronavirus infections can be an alternative approach that could help to discover potential antiviral molecules rather quickly (21,22). To this end, structure-based virtual screening approach was used for identifying inhibitor molecules targeting SARS-CoV-2 virus-host cell interaction, using the crystal structure of ACE2 complexed with S-RBD and the newly released whole genome sequence of SARS-CoV-2 (23). Given that ACE2 is the key receptor for S-RBD, the hotspot 31 and hotspot 353 residues were targeted in this study, to identify small molecules that could help in preventing SARS-CoV-2 infections. This framework was reiteratively applied to identify small molecules targeting both the virus binding hotspot 31 and hotspot 353 on ACE2 receptor, and the residues of S-RBD of SARS-CoV-2. Binding interactions of antiviral drugs identified in this study, were validated using *in silico* structure-based molecular docking and simulation approach. This study has identified drug molecules, which can be directly tested for *in vitro* and *in vivo* studies, to combat a global threat of COVID-19.

MATERIALS AND METHODS

Hardware and software

All computational study work was done on macOS Mojave workstation with 8-core Intel Xeon E5 processor. MD simulation studies were performed on LINUX workstation using GROMOS96 43a1 force field in GROMACS 5.1.1 suite. Bioinformatics software, such as PyRx 0.8 (24), Open Babel (25), AutoDock Vina (26), PyMol (27), GROMACS (28) and online resources like SWISS MODEL (29), HADDOCK (30), RCSB PDB (31), NCBI (32), ProCheck

at RCSB validation server (33), ProSA-web (34), SAVES-Verify3D server (35), etc. were used in this study.

3D homology model generation of S1-Subunit

Homology modeling for S1-subunit of S-protein (residues 319-529) of SARS-CoV-2 was done using SWISS-MODEL. NCBI was used to obtain target sequence for SARS-CoV-2 based on whole genome sequence of SARS-CoV-2 (GenBank accession number: MN908947.3). Crystal structure of SARS-CoV-2 S-protein (PDB ID: 6VSB) was the template hit obtained which has a sequence identity of ~99%. This was used as a template to build three-dimensional model of S-RBD protein of SARS-CoV-2. Quality assessment of the predicted 3D homology model of S-RBD protein was done using PROCHECK, followed by validation using ProSA plot, SAVES server, and Verify 3D. The best-mapped model with the least number of residues in the disallowed region was selected and used for the virtual screening to identify drug molecules that bind S-RBD.

Choice of ligand library

For structure-based repurposing of clinically approved drugs, LOPAC drug library (Library of Pharmacologically Active Compounds, Sigma-Aldrich,St. Louis, MO) of ~1280 molecules, was used for screening to find potential antiviral drugs. These drug molecules were docked into crystal structures of ACE2 and modeled S-RBD of SARS-CoV-2.

Structure-based virtual screening against ACE2 receptor and S-RBD

For this study, crystal structure of ACE2 receptor protein (PDB ID: 2AJF) and the spike protein S-RBD, which has been modeled using template of S-protein of SARS-CoV-2 (PDB ID: 6VSB), was used. The three dimensional structures of drugs or small chemical molecules retrieved from LOPAC library were of SDF type. Open Babel software was used to convert all ligands into PDBQT type. AutoDock Vina (Version 4.2) and PyRx were used to screen FDA approved LOPAC library of drug molecules centering around hotspot 31 and hotspot 353 residues of ACE2 protein of the host cell. Additionally modeled structure of S-RBD of SARS-CoV-2 was also used for *in silico* screening of therapeutic drugs from LOPAC compound library, targeting important residues (Leu455, Phe486, Asn487, Gln493, and Ser494), responsible for recognizing hotspot 31 and hotspot 353 of ACE2 receptor. Top hit drug molecules, targeting specific residues of ACE2 and S-RBD, were selected and further analyzed by AutoDock Vina for identifying specific interactions involved in binding of molecules to the targets.

Molecular docking

Molecular docking studies of selected drugs into protein targets were carried out using AutoDock Vina. Two different sets of docking studies were conducted- one set for modeled S-RBD of SARS-CoV-2 and the other set for ACE2 protein of the host cell. For both studies, proteins were pre-processed by removal of all water and addition of kollman charges. Hydrogen bond (H-bond) optimization was done and Gasteiger charges were added to it using AutoDock MGL tools 1.5.6. A receptor grid-box was generated by AutoGrid4 with grid box dimensions of

60 Å x 80 Å x 60 Å with spacing of 0.447 Å centering around hotspot residues Lys31, Glu35, Asp38 and Lys353 for ACE2 protein. Grid box for S-RBD was also set with spacing of 0.442 Å and dimensions of 62 Å x 82 Å x 82 Å centering around residues Leu455, Phe486, Asn487, Gln493 and Ser494. Lamarckian Genetic Algorithm (GA) in combination of grid based energy evaluation method was used for docking. The program was run for a total number of 50 Genetic algorithm runs. Other parameters were set as default and the final result obtained was analyzed manually by PyMol and LigPlot.

Molecular dynamics simulation

Both ACE2 protein and S-RBD protein, and their respective screened drug molecules were subjected to molecular dynamics (MD) simulation studies to assess the flexibility and stability of protein-ligand interactions. For this purpose, GROMACS 5.4.1 suite was used to carry out all simulation studies using GROMOS96 43a1 force field on a LINUX-based workstation. Ligand parameters and topology files were generated using PRODRG server. Furthermore for solvation, ions and water molecules were added to neutralize whole cubic system. Using steepest descent method, energy minimization step was performed followed by equilibration of constant number of particles, volume, and temperature (NVT), constant number of particles, pressure, and temperature (NPT). NVT equilibration was done at 300K with short range electrostatic cut-off of 1.2nm and regulation of temperature was done by using Berendsen temperature coupling method. Further, the next phase of equilibration NPT was performed and coordinates were generated at every 1 ps. Finally, 50ns MD production run was performed with an integration time frame of 2fs and the trajectories were generated after every 10ps. The conformations generated during the production step were used for calculating RMSD values of protein-ligand complexes.

RESULTS

Identification of ACE2 receptor binding drug molecules

To mediate entry inside host cell, the trimeric S-glycoprotein of coronavirus binds to the host cell surface receptor ACE2 via S-RBD of S-protein (36). ACE2 is a membrane glycoprotein containing a claw like N- terminal peptidase domain made up of α-helical lobes present on outer surface, responsible for interacting with bowl-shaped cavity on S-RBD (20). In the sequence of SARS-CoV-2, the S-RBD residues directly interacting with ACE2 receptor, are similar to that of SARS-CoV, strongly signifying that ACE2 is playing a central role in SARS-CoV-2 entry into host-cell (36,37). Lys31 and Lys353 are reported to be the two main hotspot virus-binding sites located on ACE2 at the virus-receptor interface for NL63-CoV and SARS-CoV (1,20). Recent published data suggests that hotspot 31 is made up of salt bridge between Lys31 and Glu35, and hotspot 353 comprises of a salt bridge between Lys353 and Asp38, both buried in hydrophobic environment (1,8).

Therefore, the virus binding hotspots on ACE2 receptor were targeted to identify small drug molecules from FDA approved LOPAC library, which is expected to block ACE2 receptor and its interactions with the virus. Computer based high throughput screening was done using PyRx and AutoDock Vina with a grid box centering on Lys31 and Lys353 hotspot residues

(**Figure 1A**). The top hit ligand candidates were scored based on their binding energies for ACE2 protein. Best 5 molecules were selected on the basis of RMSD values, molecular interactions with interface residues and binding energies. GR 127935 hydrochloride hydrate, GNF-5, RS504393, TNP and Eptifibatide acetate were the top drugs obtained, which targeted ACE2 host-virus interface (**Figures 1B-F**). To gain further insights into the interactions present at ligand-ACE2 interface, each of the selected drug molecule was docked into ACE2 protein using AutoDock Vina. Top scoring ligands based on their binding affinities and visual analysis of docked complexes for their capability to form H-bond and other interactions with ACE2 virus-binding motifs are documented in **Table 1**.

Comparison of molecular interactions between ACE2 receptor and ligands

Molecular docking using AutoDock Vina, for the top 5 drug molecules of the LOPAC library obtained by screening were analyzed by PyMol and LigPlot. GR 127935 hydrochloride hydrate (GR hydrochloride) displayed highest binding energy (-11.23 kcal/mol), makes 2 H-bonds with ACE2 receptor (**Figure 2A**). Apart from these, hydrophobic interactions are also observed including hotspot residue Lys353 and other adjacent residues like Phe40, Ala348, Trp349, Gly352, Gly354, His378, Asp382, Tyr385, Ala386, Phe390, Arg393, Asn394 and His401 clearly depicting its ability to bind and block interactions with residues of hotspot 353 (**Figures 1B, 2A**). Ligand GNF-5 (B.E= -7.57 kcal/mol) interacts with Lys353 through hydrophobic bond (**Figures 1C**). GNF-5 possessed maximum numbers of hydrogen bonds involving Trp69, Asp350, Gly352, Phe390 and Arg393 residues along with hydrophobic interactions, displaying its affinity towards hotspot 353 (**Figures 1C, 2B**). Key hydrophobic interactions playing a significant role for these ligands involve Phe40, Lys353, Gly354 and Asn394 along with other residues (**Figures 1B,C, 2A,B**). These interactions clearly demonstrate that GR hydrochloride and GNF-5 are drug molecules that could potentially inhibit virus, binding to hotspot 353 (**Table 1**). Docked conformations of ligand RS504393 (B.E= -8.32 kcal/mol), TNP (B.E= -7.42 kcal/mol) and Eptifibatide acetate (B.E= -6.05 kcal/mol) suggests that these ligands are displaying affinity towards residues of hotspot 31, and to some extent towards hotspot 353 also, showing hydrophobic interaction with Asp38 (**Figures 1D-F**). TNP interacts with ACE2 forming 3H-bonds with Gln42 and Glu75 whereas RS504393 interacts with ACE2 with H-bonding with Lys68. Hydrophobic interactions reported here for TNP are Lys31, Glu35, Leu39, Lys68, Phe72, Gln76 and Leu79. Rs504393 interacts with Asp30, Lys31, His34, Glu35, Asp38, Leu39, Gln42 and Phe72 through hydrophobic interactions as shown in **Table 1** (**Figures 2C, D**). Eptifibatide acetate interacts with ACE2 through 3H-bonds with residues His34, Glu75 and Gln76, and hydrophobic bonds with Lys31, Glu35, Asp38, Leu39, Lys68 and Phe72, displaying its greater affinity towards hotspot 31. MD simulation was performed to check the stability of selected drugs with ACE2 receptor protein. RMSD curves for all protein-ligand complexes attained equilibrium after 20ns and fluctuations were found to be in the range of 0.25nm to 0.31nm for GR hydrochloride, RS504393, TNP and Eptifibatide acetate, and 0.35nm to 0.4nm for GNF-5, depicting that binding of drugs to ACE2 protein resulted in formation of stable complexes (**Figure S1 A-E**). Given the results from all set of dockings, our study provides evidence that these identified molecules interacting with hotspot 31 and hotspot 353 specifically, if repurposed would prove to be potential drugs for further studies.

Structure of S-RBD of SARS-CoV-2

The key determinant of host specificity of coronavirus is the surface anchored S-protein responsible for recognizing host cell receptor ACE2 through its S1 subunit. The central residues of S1 (NL63-CoV: 481-615; SARS-CoV: 306-527 for) are reported to contain the receptor binding domain (RBD), responsible for high affinity binding to ACE2 receptor (20). Because of sequence similarities between RBD of SARS-CoV-2 and SARS-CoV, it is hypothesized that SARS-CoV-2 infects the host cell via ACE2 receptor through binding of its RBD region of the S-protein (7).

Drug molecules targeting the S-protein has the potential to cure COVID-19 infections and to tackle the pandemic. In this study, S1 subunit of SARS-CoV-2 was targeted by *in silico* approach to repurpose drug molecule that binds the S-RBD and blocks its interaction with ACE2 receptor, rendering it incapable to infect host cell. Since the newly published structure of SARS-CoV-2 S-protein (PDB ID: 6VSB) lacks important loop residues of S-RBD domain proposed to be involved in receptor binding, therefore a homology model was generated utilizing it as a template (**Figures 3A, B**). A 3D model of S1 subunit of SARS-CoV-2 S-protein, was predicted using SWISS MODEL (NCBI reference sequence: MN908947.3) and the pre-fusion structure of SARS-CoV-2 spike glycoprotein (PDB ID: 6VSB) was used as template (**Figure 3**). The 3D model obtained for S-RBD of SARS-CoV-2 was validated using PROCHECK, ProSA and SAVES-Verify 3D server. Ramachandran Plot of the predicted model of S-RBD domain of spike protein by PROCHECK and SAVES-Verify 3D server suggests that 82.8% of the residues are present in the core allowed region, 15.2% in allowed region, 1.4 % in generously allowed region, and only 0.7% residues in disallowed region not part of loop involved in ACE2 receptor binding (**Figure 4A**). Overall, the modeled structure was good as more than 99% of the residues, after summing up, were in allowed region of Ramachandran plot.

Further validation of model was done using ProSA, where the protein folding energy obtained through it was in good agreement with the plot. The Z-score value obtained through it was -7.39 (**Figure 4B**). Overall quality factor evaluated by VERIFY3D was ~85%. These results suggested that the modeled S-RBD of SARS-CoV-2 is acceptable and could be further used for structure-based virtual screening. This predicted model of S-RBD of SARS-CoV-2 was used for protein-protein docking studies to identify its residues interacting with ACE2 receptor and to further screen small drug molecules which could block these interactions of S-RBD–ACE2 interface. The predicted homology model for S1 subunit of S-protein was submitted in PMDB database (PMDB ID: PM0082972), and the HADDOCK tool was used to identify interacting residues between receptor and S-RBD of S-protein (**Figure S2**).

Receptor binding residues on S-RBD of SARS-CoV-2

Crystal structure of S-protein of SARS-CoV-2 (PDB ID: 6VSB), published recently, lacks residues present in the S-RBD region of SARS-CoV-2. Chimeric S-RBD of SARS-CoV-2 (PDB ID: 6VW1) has been reported, but the structure comprises majorly of SARS-CoV residues and contains only S-RBM of SARS-CoV-2. Therefore, S1-subunit of SARS-CoV-2

was modeled and used to identify molecular interactions with ACE2 receptor using HADDOCK based protein-protein docking tool. Hotspot 31 and hotspot 353 were fed as central residues on the basis of which S-RBD residues of the predicted model were docked (**Figure S2**).

Identification of SARS-CoV-2 S-RBD binding drugs

The residues present at the interface region of S-RBD–ACE2 were targeted and used for structure-based screening and selection of drug molecules using PyRx. With respect to interface residues, AutoDock Vina based docking calculations were performed for top five molecules selected on the basis of RMSD values, binding energies and for their ability to form H-bonds and hydrophobic bonds. KT203 and BMS195614 were the first hits obtained having binding energies of -8.73 and -8.25 kcal/mol respectively which were more than that of KT185 (-8.16 kcal/mol) and RS504393 (-7.67 kcal/mol) (**Figures 5B-E**). Interestingly drug RS504393 is identified for both ACE2 (-8.32 kcal/mol) and S-RBD (-7.67 kcal/mol) (**Figure 5E**). A complete list of polar and hydrophobic interactions between the five ligands and S-RBD interface are shown in **Table 2**.

Comparison of molecular interactions between S-RBD residues and ligands

Two dimensional plot of the molecular interaction network of the ligands with S-RBD were prepared using LigPlot, and the docked poses for each of these molecules are represented in **Figure 5**. The results obtained after docking calculations suggests that the S-RBD residues of SARS-CoV-2 interacting with the ligands are Leu455, Phe486, Asn487, Gln493, and Ser494. The residues Leu455, Phe486 and Gln493 of S-RBD have been reported to interact with hotspot 31, whereas residues Asn487 and Ser494 are described to interact with hotspot 353 of SARS-CoV-2 (1,36). Out of 1280 drug molecules, KT203 and BMS195614 displayed highest binding energies of -8.73 kcal/mol and -8.25 kcal/mol respectively and interact with S-RBD residues through one and three H-bond respectively (**Figures 5B,C**). In the docked conformations, KT203 and BMS195614 displayed maximum number of hydrophobic interactions with residues responsible for recognizing both hotspot 31 and hotspot 353 (**Figures 5B,C, 6A,B**). Interestingly KT203 binds with Leu455, Phe486, Tyr489, Gln493 and Ser494 through hydrophobic interactions, all of which are known to be a part of virus binding motif of ACE2 receptor. Additionally other hydrophobic interactions obtained for KT203 are Tyr449, Asn450, Tyr451, Leu452, Lys458, Pro491 and Leu492. BMS195614 interacts with Asn487 and Ser494 through H-bond and with Leu455, Lys458, Cys488, Tyr489, Phe490, Pro491 and Gln493 through hydrophobic interactions. KT185 interacts with Arg457, Phe486, Asn487, Tyr489, Leu492 and Gln493 through hydrophobic interactions (**Figures 5D, 6C**). Residues Gly485 and Phe490 are observed to bind with KT185 through H-bonds. RS504393 and GSK1838705A are also observed to interact with residues responsible for recognizing both hotspots (**Figures 5E,F, 6D,E**). RS504393 was found to be a common ligand for ACE2 receptor and S-RBD, and displayed polar interaction with Asn487 and Leu492 (**Figures 5E, 6D**) along with few hydrophobic interactions with Leu452, Cys488, Phe486, Tyr489, Phe490, Gln493 and Ser494. GSK1838705A displayed hydrophobic interactions with residues Tyr449, Leu452, Leu455, Cys488, Tyr489, Phe490, Pro491 and Ser494 whereas polar bonding was observed for Leu492 and Gln493. It is observed that additional H-bonds are obtained in docked complexes i.e.,

Gly485, Phe490 and Leu492 which seems to contribute towards stability of docked drug complexes. Cys488, Tyr489, Pro491, and Leu492 were additional important and common hydrophobic interactions observed for most of the ligands, different from ACE2 interacting residues (**Table 2**). To monitor the stability of protein and ligands, MD simulation was carried out. The RMSD curve converged well after 25ns for GSK1838705A, and after 20ns for BMS195614, KT185, KT203 and RS504393, and thereafter remained stable upto 50ns for all ligands. Fluctuations in RMSD values were in range of 1.6nm to 1.7nm for GSK1838705A, BMS195614 and RS504393, and 2.0nm to 2.1nm for KT185. Overall, the RMSD results show that the binding of each compound to S-RBD of S-protein is stable. (**Figures S3 A-E**)

DISCUSSION

Understanding the virus-receptor recognition mechanism responsible for COVID-19 infection, pathogenesis and host range provides direction to develop antiviral therapy to combat and cure this global pandemic of 2020. There is no drug or antiviral treatment against SARS-CoV-2, and development of new drug molecules will take time. Moreover, WHO has already declared COVID-19 infection as a global pandemic problem, therefore repurposing drugs available for other diseases would be beneficial as these can be directly tested as anti-SARS-CoV-2 drugs and can be processed for COVID-19 trials.

Viral life cycle involves entry into the host cell after attachment to the host cell receptor, release of genetic material inside cell, synthesis of structural and non-structural proteins and genomic RNA, assembly of mature virus particles followed by budding to exit from host cell (38). RNA viruses like chikungunya virus, dengue virus, Ebola virus, SARS, MERS, Sindbis virus etc. can thus be targeted at each of these steps of their life cycle to combat infections caused by them (39). Antiviral drugs blocking entry of virus or acting on replication stages have been reported against dengue, chikungunya virus and other similar RNA viruses (40,41). Studies suggest that targeting the capsid synthesis step could also prevent budding stage of virus (42,43). Antiviral drugs against SARS-CoV-2 can also be identified by targeting the virus at these stages of life cycle.

Viral S-protein present on the envelope of SARS-CoV-2 is responsible for mediating interaction with ACE2 receptor present on the host cells via its RBD unit. Since this interaction is essential for SARS-CoV-2 entry into the host cell and infection, drugs targeting S-RBD–ACE2 interface protein-protein interactions could potentially inhibit the virus entry into host cell and thus, provide quick solution to control SARS-CoV-2 infections. Structure-based drug repurposing using high throughput virtual screening tools has been used to identify FDA approved drugs which could block interactions of SARS-CoV-2–ACE2 receptor. The results of this study of modeling of S-RBD of SARS-CoV-2, coupled with rapid screening of FDA approved LOPAC library drug molecules against both S-RBD and receptor ACE2, have identified potential drugs that are proposed to inhibit virus infection.

In concordance with the results obtained after drug library screening, molecular docking studies were performed to gain insights into the binding mode and crucial molecular interactions of the selected ligands with ACE2 protein of the host cell and the S-RBD protein of

SARS-CoV-2. With regards to ACE2 inhibitors, GR hydrochloride and GNF-5 interact with residues of hotspot 353 preferably and the remaining three, RS504393, TNP, and Eptifibatide acetate interact well with residues adjacent to hotspot 31 through polar as well as hydrophobic bonds. Structure-based rational drug design approach can be used to design a drug molecule combining these two ligands that will possess ability to bind both hotspot 31 and hotspot 353. KT203 and BMS195614 were predicted to be potential inhibitors against S-RBD of SARS-CoV-2 in pursuit of their high binding energies and owing to their ability to interact and block key RBD residues responsible for recognizing hotspot 31 and hotspot 353 of SARS-CoV-2 (**Figures 5B,C, 6A,B**). KT185, RS504393, and GSK1838705A were the other ligands obtained, and KT185 was observed to display a higher affinity towards S-RBD residue interacting with hotspot 31 by displaying interactions with Phe486 and Gln493 (**Figures 5D-F**). Intriguingly RS504393 was screened to be common for both S-RBD and ACE2 interface residues, with a higher affinity towards ACE2 virus binding motif.

Virtual screening of compounds libraries provided some promising FDA approved drugs which are either proposed to inhibit RNA viruses by targeting entry or replication steps of their life cycle, or by providing anti-inflammatory effects. GNF-5 identified in our study, is already a reported drug that blocks coronavirus S-protein induced fusion, prior to hemifusion, by inhibiting Abl kinase (44,45). This drug also inhibits Dengue virus entry by its action on Abl kinase. Similarly TNP, identified against ACE2 is a selective inhibitor of Inositol hexakisphosphate kinase (IP6K) and Akt signaling, reported to be responsible for inhibiting MERS-CoV infection (46,47). GR hydrochloride is an antagonist of 5-HT1B/1D serotonin receptor, and also plays a role in inhibiting entry of Ebola virus entry into host cell (48). Eptifibatide acetate protects lungs from inflammations caused by influenza virus (49). KT185 and KT203, inhibitors of S-RBD protein of SARS-CoV-2 are known to exert anti-inflammatory role on lungs (50). GSK1838705A is known to reduce inflammations posed by infections caused by influenza virus, whereas BMS195614, another inhibitor against S-RBD is proposed to inhibit Hepatitis B virus infection (51,52). Drug RS504393, identified against both ACE2 and S-RBD, targets chemokine receptor, a mechanism by which SARS-CoV interferes with host immune system (53). Detailed role of screened compounds along with target sites are summarized in **Table 3**. Therefore these molecules are expected to be effective against virus by not only targeting the virus entry step but also by acting as anti-inflammatory drugs against cells and tissue damages caused by SARS-CoV-2 infection.

AUTHOR CONTRIBUTIONS

YSM involved in the conceptualization and manuscript draft and reviewing. ST involved in the conceptualization, design, analysis of data and manuscript drafting. SC performed all computational studies and have analyzed the data.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGMENTS

REFERENCES

1.   Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* (2020) **94**: doi:10.1128/jvi.00127-20

2.   Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* (2020) **25**: doi:10.2807/1560-7917.ES.2020.25.3.2000045

3.   Situation reports 84 for April 13th , 2020. *WHO* (2020)

4.   Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS- CoV- 2. *J Med Virol* (2020)jmv.25726. doi:10.1002/jmv.25726

5.   WHO | Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. *WHO* (2015)

6.   WHO | Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. *WHO* (2016)

7.   Huang Q, Herrmann A. Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). *bioRxiv* (2020)2020.02.01.930537. doi:10.1101/2020.02.01.930537

8.   Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. *J Clin Microbiol* (2010) **48**:2940–2947. doi:10.1128/JCM.00636-10

9.   Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, Tiwari R, Chaicumpa W. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. *Vet Q* (2020) **40**:68–76. doi:10.1080/01652176.2020.1727993

10.   Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. *J Travel Med* (2020) **27**: doi:10.1093/jtm/taaa020

11.   Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* (2020) **323**:1239–1242. doi:10.1001/jama.2020.2648

12.   Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res* (2020) **177**:104762. doi:10.1016/j.antiviral.2020.104762

13.   Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing. *PLoS One* (2012) **7**: doi:10.1371/journal.pone.0050366

14.   Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. *Hum Vaccin Immunother* (2020)1–7. doi:10.1080/21645515.2020.1735227

15.   Hoffmann M, Kleine-Weber H, Schroeder S, Mü MA, Drosten C, Pö S, Krü N, Herrler T, Erichsen S, Schiergens TS, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* (2020) **181**:1–10. doi:10.1016/j.cell.2020.02.052

16.   Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2. *J Biol Chem* (2004) **279**:3197–3201. doi:10.1074/jbc.C300520200

17.   Bonavia A, Zelus BD, Wentworth DE, Talbot PJ, Holmes K V. Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229E. *J Virol* (2003) **77**:2530–2538. doi:10.1128/jvi.77.4.2530-2538.2003

18.   Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, Yuen K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect* (2020) **9**:221–236. doi:10.1080/22221751.2020.1719902

19.   Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med* (2020)1–3. doi:10.1038/s41591-020-0820-9

20.   Wu K, Li W, Peng G, Li F. Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. *Proc Natl Acad Sci U S A* (2009) **106**:19970–19974. doi:10.1073/pnas.0908837106

21.   Harrison C. Coronavirus puts drug repurposing on the fast track. *Nat Biotechnol* (2020) **38**:379–391. doi:10.1038/d41587-020-00003-1

22.   Li F, Li W, Farzan M, Harrison SC. Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science (80-)* (2005) **309**:1864–1868. doi:10.1126/science.1116480

23.   Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, et al. A new coronavirus associated with human respiratory disease in China. *Nature* (2020) **579**:265–269. doi:10.1038/s41586-020-2008-3

24.   Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. *Methods Mol Biol* (2015) **1263**:243–250. doi:10.1007/978-1-4939-2269-7_19

25.   O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. *J Cheminform* (2011) **3**:33. doi:10.1186/1758-2946-3-

26. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* (2010) **31**:455–461. doi:10.1002/jcc.21334

27. Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.8. (2015)

28. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics* (2013) **29**:845–854. doi:10.1093/bioinformatics/btt055

29. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* (2018) **46**:W296–W303. doi:10.1093/nar/gky427

30. Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. *J Am Chem Soc* (2003) **125**:1731–1737. doi:10.1021/ja026939x

31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. *Nucleic Acids Res* (2000) **28**:235–242. doi:10.1093/nar/28.1.235

32. Coordinators NR. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* (2016) **44**:D7–D19. doi:10.1093/nar/gkv1290

33. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl Crystallogr* (1993) **26**:283–291. doi:10.1107/s0021889892009944

34. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res* (2007) **35**:W407–W410. doi:10.1093/nar/gkm290

35. Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: Assessment of protein models with three-dimensional profiles. *Methods Enzymol* (1997) **277**:396–404. doi:10.1016/S0076-6879(97)77022-8

36. Jian Shang, Gang Ye , Ke Shi, Yushun Wan, Chuming Luo , Hideki Aihara, Qibin Geng, Ashley Auerbach FL. Structural basis for receptor recognition by the novel coronavirus from Wuhan. (2020)1–19. doi:10.21203/rs.2.24749/v1

37. Yan R, Zhang Y, Li Y, Xia L, Zhou Q. Structure of dimeric full-length human ACE2 in complex with B 0 AT1. *bioRxiv* (2020) doi:10.1101/2020.02.17.951848

38. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. *Nat Rev Microbiol* (2004) **2**:109–122. doi:10.1038/nrmicro817

39. Kaur R, Neetu, Mudgal R, Jose J, Kumar P, Tomar S. Glycan-dependent chikungunya

viral infection divulged by antiviral activity of NAG specific chi-like lectin. *Virology* (2019) **526**:91–98. doi:10.1016/J.VIROL.2018.10.009

40. Singh H, Mudgal R, Narwal M, Kaur R, Singh VA, Malik A, Chaudhary M, Tomar S. Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease. *Biochimie* (2018) **149**:51–61. doi:10.1016/j.biochi.2018.04.004

41. Mudgal R, Mahajan S, Tomar S. Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase. *FEBS Lett* (2020) **594**:678–694. doi:10.1002/1873-3468.13642

42. Sharma R, Kesari P, Kumar P, Tomar S. Structure-function insights into chikungunya virus capsid protein: Small molecules targeting capsid hydrophobic pocket. *Virology* (2018) **515**:223–234. doi:10.1016/j.virol.2017.12.020

43. Sharma R, Fatma B, Saha A, Bajpai S, Sistla S, Dash PK, Parida M, Kumar P, Tomar S. Inhibition of chikungunya virus by picolinate that targets viral capsid protein. *Virology* (2016) **498**:265–276. doi:10.1016/J.VIROL.2016.08.029

44. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. *J Gen Virol* (2018) **99**:619–630. doi:10.1099/jgv.0.001047

45. Clark MJ, Miduturu C, Schmidt AG, Zhu X, Pitts JD, Wang J, Potisopon S, Zhang J, Wojciechowski A, Hann Chu JJ, et al. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral e Protein. *Cell Chem Biol* (2016) **23**:443–452. doi:10.1016/j.chembiol.2016.03.010

46. Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, Huang AS, Dailey MJ, et al. Inositol pyrophosphates inhibit akt signaling, thereby regulating insulin sensitivity and weight gain. *Cell* (2010) **143**:897–910. doi:10.1016/j.cell.2010.11.032

47. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, et al. Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis. *Antimicrob Agents Chemother* (2015) **59**:1088 LP – 1099. doi:10.1128/AAC.03659-14

48. Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. *J Virol* (2015) **89**:9932 LP – 9938. doi:10.1128/JVI.01337-15

49. Lê VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin JL, Adrian I, Errazuriz-Cerda E, Frasquilho S, Antunes L, et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. *Am J Respir Crit Care Med* (2015) **191**:804–819. doi:10.1164/rccm.201406-1031OC

50. Bottemanne P, Paquot A, Ameraoui H, Alhouayek M, Muccioli GG. The α/β–hydrolase domain 6 inhibitor WWL70 decreases endotoxin-induced lung inflammation in mice, potential contribution of 2-arachidonoylglycerol, and lysoglycerophospholipids. *FASEB J*

(2019) **33**:7635–7646. doi:10.1096/fj.201802259R

51.   Li G, Zhou L, Zhang C, Shi Y, Dong D, Bai M, Wang R, Zhang C. Insulin-Like Growth Factor 1 Regulates Acute Inflammatory Lung Injury Mediated by Influenza Virus Infection . *Front Microbiol* (2019) **10**:2541. Available at: https://www.frontiersin.org/article/10.3389/fmicb.2019.02541

52.   Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M, et al. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. *J Biol Chem* (2015) **290**:5673–5684. doi:10.1074/jbc.M114.602540

53.   Kwiatkowski K, Piotrowska A, Rojewska E, Makuch W, Mika J. The RS504393 Influences the Level of Nociceptive Factors and Enhances Opioid Analgesic Potency in Neuropathic Rats. *J Neuroimmune Pharmacol* (2017) **12**:402–419. doi:10.1007/s11481-017-9729-6

54.   Yang D, Tong L, Wang D, Wang Y, Wang X, Bai C. Roles of CC chemokine receptors (CCRs) on lipopolysaccharide-induced acute lung injury. *Respir Physiol Neurobiol* (2010) **170**:253–259. doi:10.1016/j.resp.2010.02.002

55.   Hsu K-L, Tsuboi K, Chang JW, Whitby LR, Speers AE, Pugh H, Cravatt BF. Discovery and Optimization of Piperidyl-1,2,3-Triazole Ureas as Potent, Selective, and in Vivo-Active Inhibitors of α/β-Hydrolase Domain Containing 6 (ABHD6). *J Med Chem* (2013) **56**:8270–8279. doi:10.1021/jm400899c

56.   Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. *Mol Cancer Ther* (2009) **8**:2811–2820. doi:10.1158/1535-7163.MCT-09-0423

57.   Hammond LA, Krinks CH Van, Durham J, Tomkins SE, Burnett RD, Jones EL, Chandraratna RAS, Brown G. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells. *Br J Cancer* (2001) **85**:453–462. doi:10.1054/bjoc.2001.1939

TABLES

Table 1. Binding energies, polar and hydrophobic interaction of selected drugs screened against ACE2 receptor of host cell.

Ligand	Binding Energy (kcal/mol)	Interactions		
		H-Bonds	Bond length($\mathring{A}$)	Hydrophobic interactions
GR hydrochloride	-11.23	N5-OE2(Glu37)	2.87	Phe40, Ala348, Trp349, Gly352, Lys353,Gly354, His378, Asp382, Tyr385, Ala386, Phe390, Arg393, Asn394, His401
		O2-N(Asp350)	2.95	
RS504393	-8.32	O2-NZ(Lys68)	2.79	Asp30, Lys31, His34, Glu35, Asp38, Leu39, Gln42, Phe72
TNP	-7.42	O2-NE2(Gln42)	2.94	Lys31, Glu35, Leu39, Lys68, Phe72, Gln76, Leu79
		N2-OE2 & N5-OE2(Glu75)	2.92 & 2.60	
GNF-5	-7.57	O3-NE1(Trp69)	2.83	Glu37, Phe40, Leu73, Lys353, Gly354, Phe356, Leu391, Asn394
		O2-OD1 & N3-OD1(Asp350)	2.57 & 2.82	
		O2-N(Gly352)	3.08	
		O-N1(Phe390)	2.64	
		O1-NH1(Arg393)	2.75	
Eptifibatide acetate	-6.05	O-N10(His34)	2.88	Lys31, Glu35, Asp38, Leu39, Lys68, Phe72
		N11-OE2(Glu75)	2.75	
		N9-NE2(Gln76)	3.27	

Table 2. Binding energies, polar and hydrophobic interaction of selected drugs screened against S-RBD of SARS-CoV-2.

Ligand	Binding Energy (kcal/mol)	Interactions		
		H-Bonds	Bond length(Å)	Hydrophobic interactions
KT203	**-8.73**	O3-O(Phe490)	2.85	Tyr449, Asn450, Tyr451, Leu452, Leu455, Lys458, Phe486, Tyr489, Pro491, Leu492, Gln493, Ser494
BMS195614	**-8.25**	N2-O(Asn487)	2.94	Leu455, Lys458, Cys488, Tyr489, Phe490, Pro491, Gln493
		N1-O(Leu492)	2.72	
		O3-OG(Ser494)	2.91	
KT185	**-8.16**	N4-O(Gly485)	2.75	Arg457, Phe486, Asn487, Tyr489, Leu492, Gln493
		O2-N(Phe490)	2.61	
RS504393	**-7.67**	O2-N & N2-O (Asn487)	2.94 & 2.75	Leu452, Cys488, Phe486, Tyr489, Phe490, Gln493, Ser494
		N3-O(Leu492)	2.61	
GSK1838705A	**-6.46**	N8-O & N4-O(Leu492)	3.14 & 2.56	Tyr449, Leu452, Leu455, Cys488, Tyr489, Phe490, Pro491, Ser494
		N2-OE1(Gln493)	2.76	

Table 3. Summarized table of drugs identified against SARS-CoV-2–ACE2 receptor interface with their reported functions anfd role on RNA viruses.

S. No	Identified Drugs	Target in SARS-CoV-2	Reported function of drug	Inhibitory role on RNA viruses
1	**RS504393**	SARS-CoV-2 receptor ACE2 and spike protein	Treatment of lung injury and bronchial wall thickening (54)	• Targets the chemokine receptor CCR2, responsible for intense up-regulation of chemokines, and represents a mechanism by which SARS-CoV interferes the host immune response (53,54).
2	**KT185**	SARS-CoV-2 spike protein	Anti-inflammatory	• Inhibitor of ABHD6 receptor.
3	**KT203**			• Decreases macrophage activation and exerts anti-inflammatory effect on lungs (50,55).
4	**GSK1838705A**	SARS-CoV-2 spike protein	Cancer drug (56)	• Inhibitor of Insulin like growth factor-1 receptor. • Regulates acute inflammatory lungs injury mediated by influenza virus infection (51).
5	**BMS195614**	SARS-CoV-2 spike protein	Cancer drug (57)	• Inhibitor of Retinoic acid receptor. • Inhibits Hepatitis B virus infection by decreasing hepatocyte permissiveness, through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression (52).
6	**TNP**	SARS-CoV-2 receptor ACE2	Tyrosine kinase inhibitor	• Inhibitor of IP6K and Akt signalling pathway. • Responsible for inhibiting MERS-CoV infection by targeting Akt signalling (46,47).
7	**GNF-5**	SARS-CoV-2 receptor ACE2	Kinase inhibitor	• Inhibits dengue virus entry and post entry step by targeting Abl kinase inhibitor (45). • Blocks coronavirus S-protein induced fusion prior to hemifusion by Abl kinase inhibition action (44).
8	**GR127935 hydrochloride hydrate**	SARS-CoV-2 receptor ACE2	Controls vasoconstriction	• Antagonist of 5-HT1B/1D serotonin receptor. • Serotonin antagonists are potent entry inhibitors of Ebola and Marburg virus (48).
9	**Eptifibatide acetate**	SARS-CoV-2 receptor ACE2	Lung injury and inflammation	• Inhibitor of glycoprotein IIb/IIIa receptor responsible for platelet aggregation. • Protects lungs from severe injury and inflammations induced by Influenza virus (49)

FIGURE LEGENDS:

Figure 1 | The top hit selected ligands from LOPAC library showing molecular interactions with ACE2 receptor of the host cell. **(A)** Hotspot 31 and hotspot 353 residues of ACE2 receptor responsible for recognizing S-RBD of SARS-CoV-2. **(B)** Molecular interactions of GR hydrochloride with ACE2 receptor. **(C)** Molecular interactions of GNF-5 with ACE2 receptor. **(D)** Molecular interactions of RS504393 with ACE2 receptor. **(E)** Molecular interactions of TNP with ACE2 receptor. **(F)** Molecular interactions of eptifibatide acetate with ACE2 receptor. Blue ribbons corresponds to residues of ACE2 receptor and yellow stick model represents residues of Ligands. BE=Binding energy

Figure 2 | Two dimensional representation of H-bonds and hydrophobic interactions of selected drug molecules with ACE2 receptor using LigPlot. **(A)** GR hydrochloride **(B)** GNF-5 **(C)** RS5049393 **(D)** TNP **(E)** Eptifibatide acetate. Ligands are colored and represented in purple color, H-bonds are displayed in green dotted lines, red stellations represents hydrophobic interactions and residues of proteins are shown in brown color.

Figure 3 | Structure of S1 subunit of SARS-CoV-2 (PMDB ID: PM0082972). **(A)** Cartoon representation of predicted S1 subunit of SARS-CoV-2. **(B)** Superimposition of template (PDB ID: 6VSB) and modeled S-RBD of S-protein. Predicted S-RBD and template are sky blue and green in color. Encircled area represents missing residues in loops of template S-protein which are modeled for S-RBD protein of SARS-CoV-2 using SWISS MODEL.

Figure 4 | Structure validation of S1 subunit of S-protein by ProCheck and ProSA server **(A)** ProCheck Ramachandran Plot where red, bright yellow and light yellow color represents that 99.4% residues of predicted S1 subunit of S-protein are present in favorably allowed region and 0.7% residues are present in disallowed region (lightest yellow) **(B)** Energy profile of modeled spike protein of SARS-CoV-2 as calculated by ProSA.

Figure 5 | The top hit selected ligands from LOPAC library showing molecular interactions with S-RBD protein of SARS-CoV-2. **(A)** S-RBD residues responsible for interacting with ACE2 receptor. **(B)** Molecular interactions of KT203 with S-RBD. **(C)** Molecular interactions of BMS195614 with S-RBD. **(D)** Molecular interactions of KT185 with S-RBD. **(E)** Molecular interactions of RS504393 with S-RBD. **(F)** Molecular interactions of GSK1838705A with S-RBD. Blue ribbons corresponds S-RBD of spike protein of SARS-CoV-2 and violet stick model represents residues of Ligands.

Figure 6 | Two dimensional representation of H-bonds and hydrophobic interactions of selected drug molecules with S-RBD of S-protein using LigPlot. **(A)** KT203 **(B)** BMS195614 **(C)** KT185 **(D)** RS5049393 **(E)** GSK1838705A. Ligands are colored and represented in purple color, H-bonds are displayed in green dotted lines, red stellations represents hydrophobic interactions and residues of proteins are shown in brown color.